MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bromfenac sodium hydrate

CAS No. : 120638-55-3

MCE 站：Bromfenac sodium hydrate

产品活性：Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) 是一种有效的和具有口服活性的 COX 抑制剂，抑制 COX-1 和 COX-2 的 IC₅₀ 值分别为 5.56 和 7.45 nM。Bromfenac sodium hydrate 是一种溴化非甾体类抗炎/镇痛药 (NSAID)，通常用于白内障手术后的术后炎症和疼痛以及假晶状体囊状黄斑水肿 (CME) 的研究。

研究领域：Immunology/Inflammation

作用靶点：COX

In Vitro: Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myo?broblast activation in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs.

In Vivo: Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats.
Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.
Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.
Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.
Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Pyroptosis Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Acetaminophen  |  Indomethacin  |  Celecoxib  |  Aspirin  |  Ibuprofen  |  Catechin  |  NS-398  |  Diclofenac  |  20(S)-Ginsenoside Rg3  |  Naproxen  |  (-)-Epicatechin  |  Gallic acid  |  Xanthohumol  |  Sulindac  |  SC-560  |  Carprofen  |  Salicylic acid  |  Meloxicam  |  Rutaecarpine  |  Rebamipide  |  Iguratimod  |  Flufenamic acid  |  Fenofibric acid  |  Isoorientin  |  Nabumetone  |  Neochlorogenic acid  |  Piroxicam  |  Rofecoxib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。